Key Documents

View All Documentation

Y0000774

Lansoprazole for peak identification

Name: Lansoprazole for peak identification
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Lansoprazole

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₆H₁₄F₃N₃O₂S

CAS Number:

103577-45-3

Molecular Weight:

369.36

NACRES:

NA.24

PubChem Substance ID:

329831144

UNSPSC Code:

41116107

MDL number:

MFCD00866873

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

lansoprazole

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cc1c(CS(=O)c2nc3ccccc3[nH]2)nccc1OCC(F)(F)F

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)

InChI key

MJIHNNLFOKEZEW-UHFFFAOYSA-N

Gene Information

human ... ATP4A(495), ATP4B(496)

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lansoprazole for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The proton-pump inhibitor lansoprazole enhances amyloid beta production.

Nahuai Badiola et al.

PloS one, 8(3), e58837-e58837 (2013-03-23)

A key event in the pathogenesis of Alzheimer's disease (AD) is the accumulation of amyloid-β (Aβ) species in the brain, derived from the sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases. Based on a systems biology

The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.

D A Peura et al.

Alimentary pharmacology & therapeutics, 37(8), 810-818 (2013-03-05)

Higher body mass index (BMI) is a recognised risk factor for gastro-oesophageal reflux disease (GERD). Data regarding the impact of BMI on proton pump inhibitor (PPI) therapy are conflicting. To assess the impact of BMI on baseline heartburn symptom severity

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

Jyh-Ming Liou et al.

Lancet (London, England), 381(9862), 205-213 (2012-11-20)

Whether sequential treatment can replace triple therapy as the standard treatment for Helicobacter pylori infection is unknown. We compared the efficacy of sequential treatment for 10 days and 14 days with triple therapy for 14 days in first-line treatment. For

View All Related Papers

Global Trade Item Number

SKU	GTIN
Y0000774	04061833804919